Home › Compare › PSCBF vs ADC

PSCBF vs ADC: Dividend Comparison 2026

PSCBF yields 1818.18% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PSCBF wins by $4103414683.66M in total portfolio value
10 years
PSCBF
PSCBF
● Live price
1818.18%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4103414683.84M
Annual income
$3,702,796,788,756,407.00
Full PSCBF calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — PSCBF vs ADC

📍 PSCBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSCBFADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSCBF + ADC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PSCBF pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSCBF
Annual income on $10K today (after 15% tax)
$154,545.45/yr
After 10yr DRIP, annual income (after tax)
$3,147,377,270,442,946.00/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, PSCBF beats the other by $3,147,377,270,374,268.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSCBF + ADC for your $10,000?

PSCBF: 50%ADC: 50%
100% ADC50/50100% PSCBF
Portfolio after 10yr
$2051707342.01M
Annual income
$1,851,398,394,418,602.20/yr
Blended yield
90.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

PSCBF
No analyst data
Altman Z
-5.7
Piotroski
4/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSCBF buys
0
ADC buys
0
No recent congressional trades found for PSCBF or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSCBFADC
Forward yield1818.18% ✓4.13%
Annual dividend / share$2.00$3.10 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4% ✓
Portfolio after 10y$4103414683.84M ✓$178.9K
Annual income after 10y$3,702,796,788,756,407.00 ✓$80,797.29
Total dividends collected$4074760433.31M ✓$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: PSCBF vs ADC ($10,000, DRIP)

YearPSCBF PortfolioPSCBF Income/yrADC PortfolioADC Income/yrGap
1← crossover$192,518$181,818.18$10,990$580.36+$181.5K → PSCBF
2$3,477,331$3,271,336.99$12,301$860.26+$3.47M → PSCBF
3$58,943,217$55,222,471.89$14,104$1,298.62+$58.93M → PSCBF
4$937,891,469$874,822,227.57$16,691$2,008.16+$937.87M → PSCBF
5$14,012,869,532$13,009,325,660.38$20,580$3,205.09+$14012.85M → PSCBF
6$196,647,994,247$181,654,223,846.76$26,754$5,330.02+$196647.97M → PSCBF
7$2,592,865,386,485$2,382,452,032,641.56$37,196$9,345.14+$2592865.35M → PSCBF
8$32,132,661,421,271$29,358,295,457,731.54$56,244$17,523.09+$32132661.37M → PSCBF
9$374,409,247,740,494$340,027,300,019,734.44$94,286$35,736.21+$374409247.65M → PSCBF
10$4,103,414,683,838,736$3,702,796,788,756,407.00$178,949$80,797.29+$4103414683.66M → PSCBF

PSCBF vs ADC: Complete Analysis 2026

PSCBF — Stock

Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.

Full PSCBF Calculator →

ADC — REIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this PSCBF vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSCBF vs SCHDPSCBF vs JEPIPSCBF vs OPSCBF vs KOPSCBF vs MAINPSCBF vs NNNPSCBF vs EPRTPSCBF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.